Rockefeller Capital Management L.P. Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX

Rockefeller Capital Management L.P. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 281,320 shares of the company’s stock after acquiring an additional 87,372 shares during the period. Rockefeller Capital Management L.P.’s holdings in Neurocrine Biosciences were worth $39,900,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $25,000. DJE Kapital AG bought a new position in Neurocrine Biosciences during the 4th quarter valued at about $28,000. Geneos Wealth Management Inc. grew its holdings in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Meeder Asset Management Inc. raised its position in Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after purchasing an additional 202 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Neurocrine Biosciences in the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $158.29 on Monday. The stock’s fifty day moving average price is $148.53 and its 200-day moving average price is $140.77. The firm has a market cap of $15.92 billion, a P/E ratio of 24.39, a P/E/G ratio of 1.19 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $169.57.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Citigroup increased their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Piper Sandler raised their price target on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Leerink Partners boosted their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Sanford C. Bernstein initiated coverage on Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.52.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the transaction, the director owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This trade represents a 30.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the completion of the sale, the insider owned 22,374 shares of the company’s stock, valued at approximately $3,495,266.28. This represents a 62.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 355,234 shares of company stock worth $55,330,060 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.